Strategies for Broad Global access to pandemic influenza vaccines

Current Topics in Microbiology and Immunology

Volumn 333, Issue 1, 2009, Pages 471-493

  Edwards, Kathryn M ^a   Sabow, Adam ^b   Pasternak, Andrew ^b   Boslego, John W ^c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b PATH ^*  (United States)

^c PATH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; INFLUENZA VIRUS A H5N1 VACCINE; LIVE VACCINE; PANDEMIC INFLUENZA VACCINE; RECOMBINANT VACCINE; SEASONAL INFLUENZA VACCINE; UNCLASSIFIED DRUG;

CELL CULTURE; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG RESEARCH; ECONOMIC EVALUATION; EPIDEMIC; HUMAN; INVESTMENT; PANDEMIC INFLUENZA; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; REVIEW; SEASONAL INFLUENZA;

EID: 77958163866     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-92165-3_23     Document Type: Review

References (7)

1. Bernstein DI, Edwards KM, Dekker CL, Belshe R, Talbot HK, Graham IL, Noah DL, He F, Hill H. (2008) Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis 197(5):667-675
2. Brady RC, Treanor JJ, Atmar RL, Chen WH, Winokur P, Belshe R. (2007) A Phase I-II, randomized, controlled, dose-ranging study of the safety, reactogenicity, and immunogenicity of intramuscular inactivated influenza A/H5N1 vaccine given alone or with aluminum hydroxide to healthy adults. In: Abstracts of the Options for the Control of Influenza VI Meeting, Toronto, ON, Canada, 17-23 June 2007, p 204
3. Leroux-Roels Barkowski A, Vanwolleghem T et al. (2007) Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomized controlled trial. Lancet 370:580-589
4. Macroepidemiology of Influenza Vaccination (MIV) Study Group (2005) The macro-epidemiology of influenza vaccination in 56 countries, 1997-2003. Vaccine 23, 44, 5133-5143
5. Ninomiya A, Imai M, Tashiro M, Odagiri T. (2007) Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective in a mouse model. Vaccine 25:3554-3560
6. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. (2006) Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. New Engl J Med 354:1343-1351
7. Treanor JJ, Schiff GM, Hayden FG, Brady RC, Hay CM, Meyer AL, Holden-Wiltse J, Liang H, Gilbert A, Cox M. (2007) Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. JAMA 297(14):1577-1582